Zoetis Inc. (ZTS) has seen a notable decrease in holdings by firms such as Wealthspire Advisors LLC, alongside sales of its shares by entities such as the State of Alaska Department of Revenue. Despite this, there has been consistent investment by entities including Sciencast Management LP and Fidelis Capital Partners LLC. The company has experienced ups and downs in the past five years, with the
stock price fluctuating and at times decreasing due to concerns over the impact of its
arthritis drugs on pets. Regardless, investors in Zoetis have noted considerable
returns (around 60%) within the last half-decade. Recent
earnings and revenues have generally surpassed estimates, contributing to
strong growth in both areas. Challenges exist, with slower veterinary visits affecting gains and concerns raised over reported
safety issues with the company’s arthritis treatments for pets. Besides,
European investigations into competition rules have also had an impact on its perception.
Zoetis ZTS News Analytics from Thu, 02 Nov 2023 07:00:00 GMT to Sun, 14 Jul 2024 12:45:47 GMT -
Rating 3
- Innovation 5
- Information 7
- Rumor -4
